Company profile
Bolt Biotherapeutics, Inc.
NASDAQ:BOLTBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Trastuzumab Imbotolimod | phase2 | — | 2 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06921837 | phase1_2 | recruiting | 2025-05-26 | 2027-05-01 | Bolt Biotherapeutics, Inc. | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer |
| NCT04278144 | phase1_2 | terminated | 2020-02-24 | 2024-12-10 | Bolt Biotherapeutics, Inc. | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors |
| NCT06052852 | phase1 | terminated | 2023-10-11 | 2025-08-01 | Bolt Biotherapeutics, Inc. | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies |
| NCT05954143 | phase2 | terminated | 2023-11-30 | 2024-09-20 | Bolt Biotherapeutics, Inc. | Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer |
FDA applications (0)
No records yet.